cisplatinhoz

Cisplatinhoz is a term that appears to refer to cisplatin (cis-diamminedichloroplatinum(II)), a platinum-based chemotherapy agent used to treat various cancers. The spelling cisplatinhoz seems to be a colloquial or misspelled variant in some contexts. Cisplatin is one of the oldest platinum compounds and is often considered alongside carboplatin and oxaliplatin in regimens.

Cisplatin works by binding to DNA and forming crosslinks between and within strands. This interferes with DNA replication and transcription, triggering cell death, particularly in rapidly dividing cancer cells. It has a broad spectrum of activity against solid tumors and is frequently used in combination with other cytotoxic drugs or radiotherapy.

Common clinical uses include testicular germ cell tumors, ovarian cancer, urothelial cancers such as bladder cancer, and certain head and neck cancers. It is also used in other malignancies depending on the protocol and oncologist's judgment.

Administration is by intravenous infusion. Dosing regimens are tailored to the cancer type, patient kidney function, and treatment goals. Preventive measures against nephrotoxicity are routinely employed, including hydration and sometimes protective agents; electrolyte monitoring and correction are important due to magnesium and potassium losses. Cisplatin can cause acute and chronic kidney injury, hearing loss, nerve damage, nausea, and low blood counts; other adverse effects include vomiting, electrolyte disturbances, alopecia, and fatigue. Supportive care and dose adjustments help manage these toxicities.

Historically, cisplatin was discovered in the 1960s by researchers led by Barnett Rosenberg and was approved for clinical use in the late 1970s. It remains a foundational drug in oncology, often used in combination regimens such as BEP or MVAC for specific indications.